Protective effects of angiotensin II Type I receptor blocker on cerebral circulation independent of blood pressure

被引:38
|
作者
Kumai, Yasuhiro [1 ]
Ooboshi, Hiroaki [1 ]
Ago, Tetsuro [1 ]
Ishikawa, Eiichi [1 ]
Takada, Junichi [1 ]
Kamouchi, Masahiro [1 ]
Kitazono, Takanari [1 ]
Ibayashi, Setsuro [1 ]
Iida, Mitsuo [1 ]
机构
[1] Kyushu Univ, Dept Med & Clin Sci, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan
关键词
autoregulation; angiotensin II type I receptor; cerebral blood flow; free radicals; remodeling;
D O I
10.1016/j.expneurol.2007.11.028
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Angiotensin II type I receptor (AT1R) blocker (ARB) has been reported to modify hypertensive cerebrovascular changes; however, it is not clear whether its protective effects are independent of blood pressure. The aim of this study was to clarify the role of AT1R-mediated signals in cerebral circulation by the chronic treatment with telmisartan, an ARB, at a dose that did not lower the blood pressure. Male spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY) were treated for 4 weeks from 16 weeks of ages with telmisartan (SHR-L: 0.3 mg/kg/day, SHR-H: 3 ing/kg/day, WKY-H: 3 mg/kg/day) or vehicle (SHR-V, WKY-V). Superoxide measured by a chemiluminescent assay or dihydroethidium fluorescence and vascular morphology were examined for the thoracic aorta (Ao), common carotid (CCA), middle cerebral (MCA) and basilar arteries (BA). After 4 weeks of treatment, the blood pressure significantly declined in SHR-H but not in SHR-L in comparison to SHR-V. The lower limit of cerebral blood flow (CBF) autoregulation, evaluated by hemorrhagic hypotension, was significantly lower in SHR-L and SHR-H than SHR-V In both SHR and WKY, the superoxide levels in the arteries were significantly attenuated by both doses of ARB. ARB also reversed vascular hypertrophy in Ao, CCA and BA and the inward remodeling in MCA. These results suggest that chronic treatment with telmisartan may therefore improve CBF autoregulation with a restoration of the vascular structure and an attenuation of superoxide generation, even at a dose that does not lower the blood pressure. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:441 / 448
页数:8
相关论文
共 50 条
  • [21] Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker
    Uzu, Takashi
    Sakaguchi, Masayoshi
    Yokomaku, Yukiyo
    Kume, Shinji
    Kanasaki, Masami
    Isshiki, Keiji
    Araki, Shin-ichi
    Sugiomoto, Toshiro
    Koya, Daisuke
    Haneda, Masakazu
    Kashiwagi, Atsunori
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2009, 13 (04) : 300 - 306
  • [22] Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies
    Liu, Hao
    Kitazato, Keiko T.
    Uno, Masaaki
    Yagi, Kenji
    Kanematsu, Yasuhisa
    Tamura, Tetsuya
    Tada, Yoshiteru
    Kinouchi, Tomoya
    Nagahiro, Shinji
    JOURNAL OF HYPERTENSION, 2008, 26 (07) : 1435 - 1445
  • [23] Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan
    Saisho, Yoshifumi
    Komiya, Naoko
    Hirose, Hiroshi
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2006, 74 (02) : 201 - 203
  • [24] Protective Effects of the Angiotensin II Receptor Blocker Losartan on Cisplatin-Induced Kidney Injury
    Saleh, Samira
    Ain-Shoka, Afaf A.
    El-Demerdash, Ebtehal
    Khalef, Marwa M.
    CHEMOTHERAPY, 2009, 55 (06) : 399 - 406
  • [25] Agonistic Autoantibodies to The Angiotensin II Type I Receptor Enhance Blood Pressure and Renal Vascular Sensitivity to Angiotensin II in Pregnant Rats
    LaMarca, Babbette
    Brewer, Justin
    Wallace, Kedra
    Herse, Florian
    Moseley, Janae
    Dechend, Ralf
    Wallukat, Gerd
    Liu, Ruisheng
    HYPERTENSION, 2011, 58 (05) : E172 - E172
  • [26] Comparative study of blood pressure lowering effects of angiotensin II receptor blocker (ARB) monotherapy and in combination with other antihypertensives
    Kushiro, Toshio
    Saito, Ikuo
    Yamakawa, Mayumi
    Yamashita, Tomonari
    Matsushita, Yasuyuki
    Sagawa, Kei
    Hiramatsu, Katsutoshi
    JOURNAL OF HYPERTENSION, 2006, 24 : 141 - 141
  • [28] Effects of angiotensin-converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats
    Zhang, RY
    Wang, LF
    Zhang, L
    Meng, XN
    Li, SJ
    Wang, WR
    CHINESE MEDICAL JOURNAL, 2006, 119 (08) : 649 - 655
  • [29] Prevention of cardiac hypertrophy independent of elevated blood pressure by angiotensin II type 2 receptor gene transfer
    Metcalfe, BL
    Huentelman, MJ
    Parilak, LD
    Taylor, DG
    Knot, HJ
    Katovich, MJ
    Sumners, C
    Raizada, MK
    HYPERTENSION, 2003, 42 (03) : 389 - 389
  • [30] Angiotensin Receptor Blocker Protection Against Podocyte-Induced Sclerosis Is Podocyte Angiotensin II Type 1 Receptor-Independent
    Matsusaka, Taiji
    Asano, Takako
    Niimura, Fumio
    Kinomura, Masaru
    Shimizu, Akihiro
    Shintani, Ayumi
    Pastan, Ira
    Fogo, Agnes B.
    Ichikawa, Iekuni
    HYPERTENSION, 2010, 55 (04) : 967 - U288